Ethiqa XR® 1 FREE Vial Program Terms and Conditions

Terms and Conditions Ethiqa XR “1 Free Vial”   The following terms and conditions (the “Terms”) apply to the “1 Free Vial” program offered by Fidelis Animal Health, Inc. (“Fidelis”) for its Ethiqa XR product (the “Program”):

  1. Program Period: The Program will run from October 15, 2022, through December 15, 2022, or while supplies last. All vouchers for 1 Free Vial must be redeemed with your preferred Ethiqa XR distributor by no later than this date.
  2. Eligibility: Each applicant must meet all eligibility requirements for the Program, including, but not limited to, being a new Ethiqa XR customer.  A new Ethiqa XR customer is defined as a specific laboratory that has not ordered Ethiqa XR previously.  Only 1 Free Vial voucher can be redeemed per laboratory.  (If your institution has ordered previously, but your laboratory has not, you may still be eligible.)  In addition, because Ethiqa XR is a Class III drug, you must possess the appropriate DEA license in order to participate in the Program.
  3. How to Enter: Each applicant must complete a Program entry form here: ethiqaxr.com/1fv. The form must be completed in its entirety, and must include a valid email address, your preferred distributor’s name, and your account number with your preferred distributor.
  4. Voucher: If Fidelis determines that an applicant is eligible to participate in the Program, you will be provided with a unique voucher code by email with instructions to place your order for the 1 Free Vial with your preferred distributor.  You must have the voucher code available when redeeming this offer.  You are responsible for applicable taxes, if any.
  5. Governing Law: The Program is governed by these Terms, as well as by the laws of the State of New Jersey and applicable United States federal law, without regard to any conflicts of laws principles. The Program is void where prohibited, licensed, taxed or restricted by law.  By applying to participate in the Program, each applicant agrees to abide by these Terms and by the decisions of Fidelis with respect to the interpretation and application thereof, all of which are final and binding as regards all matters concerning the Program.
  6. Terms of Use and Privacy Statement: Your participation in the Program will also be governed by our Terms of Use, available here: https://fidelisah.com/terms-of-use/, and our Privacy Statement, available here: https://fidelisah.com/privacy-policy-2/, which Terms of Use and Privacy Statement are incorporated herein by reference.
  7. Limitations: The Program is limited to a single 5 ml vial containing 3.0 mL of Ethiqa XR.  Such vial will be provided to eligible applicants during the Program Period at no charge to the applicant.  Our decision as to whether an applicant is eligible to participate in the Program is final and binding
  8. Territory: The Program is only valid in the United States, Puerto Rico, and other select U.S. Territories.  The offer to participate in the Program is void where restricted or prohibited by law.
  9. Disqualification: Fidelis reserves the right, in its sole discretion, to disqualify any applicant that Fidelis determines: (a) has tampered with the application process or the operation of the Program; (b) has acted in a disruptive manner or with the intent to annoy or harass Fidelis or any other person or entity; (c) has not satisfied all eligibility requirements for the Program; or (d) to be otherwise in violation of these Terms.  Any attempt by an applicant to commit any of the above-listed acts of misconduct may be a violation of civil or criminal law and Fidelis reserves the right to seek damages from such applicant to the fullest extent permitted by law.
  10. Liability; Release: Each applicant, on behalf of himself or herself and his or her institution and laboratory (collectively, the “Releasor”) releases and holds harmless Fidelis and its officers, directors, employees, agents, suppliers, successors and assigns (collectively, the “Released Parties”) from any liability for any losses, damages or costs of any kind whatsoever (“Losses”) arising out of or resulting from (a) his or her submission of an application to enter the Program, (b) lost or delayed data transmission, (c) any other error in the administration of the Program, due to any cause, including, but not limited to, any technical malfunction, failure, interruption or defect of the Fidelis website or any network, equipment, software, or due to human error, or any combination of any of the foregoing; and/or (d) any disqualification of any applicant for any reason, including, but not limited to, a violation of these Terms or applicable laws.
  11. EXCLUSION OF CERTAIN DAMAGES: WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, NEITHER FIDELIS NOR ANY OF THE RELEASED PARTIES WILL BE LIABLE FOR ANY SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, EXEMPLARY, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR RELATING TO THE PROGRAM, HOWSOEVER CAUSED, WHETHER ARISING IN STATUTE, TORT, CONTRACT, OR OTHER LEGAL THEORY, AND REGARDLESS OF WHETHER FIDELIS OR ANY RELEASED PARTY WAS ADVISED OF THE POSSIBILITY OF THOSE DAMAGES.  ALL SUCH DAMAGES ARE EXPRESSLY DISCLAIMED AND EXCLUDED.
  12. Publicity: By participating in the Program, each applicant grants to Fidelis the right to publish that applicant’s name, city and state, and related business information both online and in print, in connection with the administration, promotion and marketing of the Program, without additional compensation, except to the extent prohibited by law.
  13. Termination: Fidelis reserves the right, in its sole discretion, to cancel, modify, suspend or terminate the Program at any time for any reason, including, but not limited to, any cause that affects the administration, security, fairness, integrity or proper conduct of the Program.

IMPORTANT SAFETY INFORMATION For Rats and Mice: Only administer Ethiqa XR by subcutaneous injection. Ethiqa XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use on mice or rats with pre-existing respiratory deficiencies. Do not keep rats on wood chip-type bedding after administration of Ethiqa XR. Use caution with concomitant administration of Ethiqa XR with drugs that cause respiratory depression. For Humans: Ethiqa XR should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids. Protective clothing is recommended to avoid direct contact with human skin or mucus membranes which could result in absorption of buprenorphine and adverse reactions. Not for use in humans. For more information, consult the Prescribing Information including the Boxed Warning.

Not for use in humans. Keep out of reach of children. For more information, consult the Prescribing Information, including the Boxed Warning.

Boxed Warning

WARNING: ABUSE POTENTIAL and LIFE-THREATENING RESPIRATORY DEPRESSION and ACCIDENTAL EXPOSURE

Abuse Potential

Ethiqa XR contains buprenorphine, a high-concentration (1.3 mg/mL) opioid agonist and Schedule III controlled substance with an abuse potential similar to other Schedule III opioids. The high concentration may be a particular target for human abuse. Buprenorphine has opioid properties that in humans may lead to dependence of the morphine type. Abuse of buprenorphine may lead to low or moderate physical dependence or high psychological dependence. The risk of abuse by humans should be considered when storing, administering, and disposing of Ethiqa XR. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (suicidal depression). Because of human safety risks, this drug should be used only with veterinary supervision.

Do not dispense Ethiqa XR.

Life-Threatening Respiratory Depression

The concentration of buprenorphine in Ethiqa XR is 1.3 mg/mL. Respiratory depression, including fatal cases, may occur with abuse of Ethiqa XR. Ethiqa XR has additive CNS depressant effects when used with alcohol, other opioids, or illicit drugs that cause central nervous system depression. Because of the potential for adverse reactions associated with accidental injection, Ethiqa XR should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids.